Novartis

Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
Fierce Pharma
Fri, 06/6/25 - 12:07 pm
Novartis
legal
Entresto
generics
MSN Pharmaceuticals
ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP
Clinical Trials Arena
Mon, 06/2/25 - 11:39 am
ASCO 2025
Novartis
Scemblix
chronic myeloid leukemia
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Yahoo/Reuters
Mon, 06/2/25 - 11:29 am
Novartis
radiotherapy
Pluvicto
prostate cancer
clinical trials
Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows
Fierce Pharma
Wed, 05/28/25 - 11:06 pm
Novartis
M&A
Regulus
5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ
Fierce Biotech
Tue, 05/27/25 - 10:11 pm
Novartis
M&A
insider trading
Chinook Therapeutics
RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies
Fierce Biotech
Tue, 05/20/25 - 10:18 am
Regenxbio
Novartis
Zolgensma
gene therapy
spinal muscular atrophy
Novartis to keep making malaria drugs even if orders dry up, Reuters reports
Tip Ranks
Mon, 05/12/25 - 11:39 am
Novartis
malaria
leprosy
Incyte, Novartis agree to settle long-running Jakafi royalty dispute just before trial
Fierce Pharma
Tue, 05/6/25 - 10:44 am
Incyte
Novartis
Jakafi
legal
Novartis pays $800M upfront to buy Regulus for phase 3-ready kidney drug
Fierce Biotech
Wed, 04/30/25 - 11:37 pm
Novartis
Regulus
M&A
kidney disease
Novartis posts better-than-expected first-quarter sales, raises full-year guidance
CNBC
Tue, 04/29/25 - 08:28 am
Novartis
earnings
Novartis scores NFL deal to tackle health outcomes
Pharma Voice
Thu, 04/17/25 - 11:22 am
Novartis
pharma marketing
NFL
As Bluesky continues to grow, opportunities abound for pharma brands
Medical Marketing and Media
Wed, 04/16/25 - 11:30 am
social media
pharma marketing
Big Pharma
Bluesky
Novartis
AstraZeneca
Bristol Myers Squibb
The 5 largest biopharma layoffs of Q1 2025
BioSpace
Fri, 04/11/25 - 11:47 am
layoffs
Novartis
Galapagos
Bristol Myers Squibb
Merck
Gilead Sciences
Amid tariff turmoil, Novartis commits to spending $23B on U.S. manufacturing
BioPharma Dive
Thu, 04/10/25 - 09:56 pm
Novartis
drug manufacturing
tariffs
The top 10 pharma R&D budgets for 2024
Fierce Biotech
Fri, 04/4/25 - 11:30 am
R&D
Merck
JNJ
Roche
AstraZeneca
AbbVie
Bristol Myers Squibb
Eli Lilly
Pfizer
Novartis
Sanofi
M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals
BioPharma Dive
Fri, 04/4/25 - 11:26 am
M&A
Big Pharma
JNJ
Intra-Cellular Therapies
IDRx
GSK
Novartis
Anthos Therapeutics
Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried
Investors Business Daily
Thu, 04/3/25 - 11:17 am
Novartis
Travere Therapeutics
FDA
kidney disease
atrasentan
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
BioSpace
Wed, 04/2/25 - 11:38 am
radiopharmaceuticals
Novartis
Bayer
AstraZeneca
Bristol Myers Squibb
Eli Lilly
FDA broadens use of Novartis’ radiopharma drug Pluvicto
BioPharma Dive
Sun, 03/30/25 - 10:36 pm
Novartis
Pluvicto
FDA
prostate cancer
radiopharmaceuticals
Novartis' Fabhalta is first FDA-approved therapy for rare disease C3G
Pharmaphorum
Fri, 03/21/25 - 11:19 am
Novartis
FDA
Fabhalta
C3 glomerulopathy

Pages